This document is an excerpt from the EUR-Lex website
Document C2006/326/80
Case C-448/06: Reference for a preliminary ruling from the Verwaltungsgericht Köln (Germany) lodged on 2 November 2006 — Firma cp-Pharma Handels GmbH v Bundesrepublik Deutschland
Case C-448/06: Reference for a preliminary ruling from the Verwaltungsgericht Köln (Germany) lodged on 2 November 2006 — Firma cp-Pharma Handels GmbH v Bundesrepublik Deutschland
Case C-448/06: Reference for a preliminary ruling from the Verwaltungsgericht Köln (Germany) lodged on 2 November 2006 — Firma cp-Pharma Handels GmbH v Bundesrepublik Deutschland
ĠU C 326, 30.12.2006, p. 38–38
(ES, CS, DA, DE, ET, EL, EN, FR, IT, LV, LT, HU, NL, PL, PT, SK, SL, FI, SV)
|
30.12.2006 |
EN |
Official Journal of the European Union |
C 326/38 |
Reference for a preliminary ruling from the Verwaltungsgericht Köln (Germany) lodged on 2 November 2006 — Firma cp-Pharma Handels GmbH v Bundesrepublik Deutschland
(Case C-448/06)
(2006/C 326/80)
Language of the case: German
Referring court
Verwaltungsgericht Köln
Parties to the main proceedings
Applicant: Firma cp-Pharma Handels GmbH
Defendant: Bundesrepublik Deutschland
Question referred
Is Commission Regulation (EC) No 1873/2003 of 24 October 2003 (1) amending Annex II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (2) void on account of a breach of higher-ranking Community law (Articles 1(1) and 3 of Council Regulation (EEC) No 2377/90 in conjunction with Article 4(1) of Council Directive 96/22/EC of 29 April 1996 (3)), in so far as application of an injection solution as a pharmaceutical form is excluded by virtue of the note marked (*) against the listing of progesterone in Annex II to Council Regulation (EEC) No 2377/90?